Meril Life Sciences Showcases LANDMARK Trial Success at EuroPCR
First-of-its-kind head-to-head TAVI trial reinforces the performance and safety of the Myval THV series
In a major development for cardiovascular health, Meril Life Sciences recently presented the one-year results from its pivotal LANDMARK trial during the esteemed Late-Breaking Trial session at EuroPCR, a leading cardiology conference. This groundbreaking trial marks a significant advancement in the assessment of transcatheter aortic valve implantation (TAVI) technology.
Essential Insights from the LANDMARK Trial
The LANDMARK trial uniquely positioned the balloon-expandable Myval THV series against the widely used balloon-expandable Sapien and self-expandable Evolut THV series in patients experiencing symptomatic severe aortic stenosis. The trial's outcomes reveal a compelling narrative about the Myval THV's performance in real-world clinical settings.
Notably, the Myval THV series showed non-inferiority to current THV options, achieving a remarkable one-year clinical efficacy composite endpoint of 13% compared to 13.1% for contemporary THVs. This slight difference underlines the reliability of Myval in clinical applications, bolstered by a one-sided 95% confidence interval.
Examining Quality of Life and Survival Rates
When considering combined endpoints of clinical efficacy and quality of life (QoL), the data suggest that Myval THV series patients experienced outcomes similar to those of other valve technologies. The results indicated a 19.5% composite endpoint for the Myval THV series versus 22.7% in contemporary options, illustrating competitive efficacy.
Survival statistics further emphasize the Myval THV’s effectiveness, with rates reaching 92.8% compared to 92.9% for contemporary alternatives. These findings speak volumes about the Myval THV’s safety and durability, confirming its suitability for everyday clinical use.
Expert Opinions on the Trial's Significance
Professor Patrick Serruys, the Chairman and Study Director of the LANDMARK trial, highlighted, "This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results represent a meaningful advancement for patients receiving TAVI, spotlighting the adaptability of Myval THV to complex anatomies. This versatility is exactly what clinicians need.”
Global Principal Investigator, Professor Andreas Baumbach, added, "The LANDMARK trial represents a substantial step forward in TAVI research. With rigorous benchmarks comparing Myval against both balloon-expandable and self-expanding platforms, this one-year data affirms Myval’s alignment with global safety and efficacy standards.”
Mr. Sanjeev Bhatt, Senior Vice President – Corporate Strategy at Meril, remarked, "The LANDMARK trial signifies a milestone not only for Meril but for the entire TAVI community. Our strong results validate the Myval THV series as a next-generation solution that improves safety, clinical efficacy, and quality of life for patients around the globe. We are committed to providing innovative technologies that elevate patient care and expand access to advanced structural heart therapies worldwide.”
The Long-Term Vision of the LANDMARK Trial
This pivotal trial is committed to following its participants for a decade, aiming to yield long-term insights into clinical outcomes, echocardiographic performance, and valve durability. These ongoing assessments are crucial for validating the sustained performance of the Myval THV series.
About the LANDMARK Trial
The LANDMARK trial stands as the first randomized non-inferiority trial evaluating the Myval THV series against existing balloon-expandable Sapien and self-expandable Evolut THV series for patients with symptomatic severe aortic stenosis. This comprehensive study involved 768 patients across 31 sites in over 16 countries. The primary safety and efficacy outcomes have been published in esteemed journals, underscoring the trial’s impact on medical science.
About Meril Life Sciences
Meril, a global leader in medical devices, is dedicated to advancing healthcare through innovative technologies. With a robust focus on R&D, Meril distributes cutting-edge solutions across more than 135 countries. The company strives to reshape healthcare by ensuring adherence to international standards and fostering partnerships for precision medical technology.
Frequently Asked Questions
What is the main objective of the LANDMARK trial?
The LANDMARK trial aims to compare the Myval THV series against other contemporary heart valve systems in patients with severe aortic stenosis.
How many patients participated in the LANDMARK trial?
A total of 768 patients participated in the LANDMARK trial, which spanned multiple international sites.
What were the key findings from the one-year results?
The one-year results indicate that the Myval THV series demonstrated comparable efficacy and safety to contemporary THV options.
Who are the key contributors to the LANDMARK trial?
Professor Patrick Serruys and Professor Andreas Baumbach are prominent figures leading the research and analysis within the trial.
What is Meril's vision for the future of healthcare?
Meril aims to innovate and expand access to advanced medical technology with a commitment to quality and precision in patient care.
